[Pharmacology of Mylaxen and re-evaluation of its clinical use].
D000293:Adolescent; D000328:Adult; D000771:Anesthesia, Intravenous; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D002802:Cholinesterases / Q000378:metabolism; D003331:Coronary Vessels / Q000187:drug effects*; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010101:Oxygen Consumption / Q000187:drug effects; D010477:Perfusion; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology*; D013390:Succinylcholine / Q000494:pharmacology
D000644:Quaternary Ammonium Compounds; D002802:Cholinesterases; D013390:Succinylcholine